-transparent.png){kind=logo}
BACKGROUND Murine monoclonal antibodies (MoAb) potentially can be used in the radioimmunodetection and radioimmunotherapy of cancer. However, the administration of these radiopharmaceuticals to humans often leads to induction of human anti-murine antibodies (HAMA). HAMA has many disadvantages, which could decrease efficacy of the murine MoAb. The purpose of this work was to produce human monoclonal antibody against a human ovarian cancer cell surface antigen (OCCSA), which was not present in normal ovarian cells. This 200-kilodalton OCCSA also was used in the present study for characterizing the human monoclonal antibody. METHODS Human monoclonal antibodies were produced in vitro by fusion of mutant myeloma cells, selected from GM1500, with human lymphoid cells immunized in vitro with purified OCCSA: The human monoclonal antibody was characterized using the following techniques: sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), native-PAGE, Western blotting followed by protein-A gold staining, immunodiffusion assays, and fluorescent antibody assays. RESULTS Human monoclonal antibody, TC5 (immunoglobulin G1), was produced and purified. It was found to be specific for ovarian cancer, while also reacting with an early stage breast cancer. TC5 did not react with any normal (i.e., nonneoplastic) cells of the ovary, uterus, cervix, endocervix, or fallopian tube, nor did it react with normal lung, heart, pancreas, liver, or breast tissue. CONCLUSIONS Human-human hybridomas produced human monoclonal antibody against OCCSA: The human monoclonal antibody, TC5, was specific for ovarian and breast cancer. TC5 did not react with any normal tissue tested. Future work will focus on the in vivo characterization of the human monoclonal antibody, after labeling with radionuclides.
T R Chaudhuri, and
K R Zinn, and
J S Morris, and
G A McDonald, and
A S Llorens, and
T K Chaudhuri
January 2008,
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society,
T R Chaudhuri, and
K R Zinn, and
J S Morris, and
G A McDonald, and
A S Llorens, and
T K Chaudhuri
June 1990,
Chinese medical journal,
T R Chaudhuri, and
K R Zinn, and
J S Morris, and
G A McDonald, and
A S Llorens, and
T K Chaudhuri
June 1995,
Experimental cell research,
T R Chaudhuri, and
K R Zinn, and
J S Morris, and
G A McDonald, and
A S Llorens, and
T K Chaudhuri
August 2007,
Antiviral research,
T R Chaudhuri, and
K R Zinn, and
J S Morris, and
G A McDonald, and
A S Llorens, and
T K Chaudhuri
November 1989,
International journal of cancer,
T R Chaudhuri, and
K R Zinn, and
J S Morris, and
G A McDonald, and
A S Llorens, and
T K Chaudhuri
October 1980,
Science (New York, N.Y.),
T R Chaudhuri, and
K R Zinn, and
J S Morris, and
G A McDonald, and
A S Llorens, and
T K Chaudhuri
November 2017,
Oncotarget,
T R Chaudhuri, and
K R Zinn, and
J S Morris, and
G A McDonald, and
A S Llorens, and
T K Chaudhuri
February 1994,
Journal of Korean medical science,
T R Chaudhuri, and
K R Zinn, and
J S Morris, and
G A McDonald, and
A S Llorens, and
T K Chaudhuri
January 1995,
Journal of the Medical Association of Thailand = Chotmaihet thangphaet,
T R Chaudhuri, and
K R Zinn, and
J S Morris, and
G A McDonald, and
A S Llorens, and
T K Chaudhuri
February 1987,
Biochemical and biophysical research communications,
